A position paper: Based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer’s disease cholesterol-lowering treatment trial (ADCLT)

Author： Sparks D.   Lopez Jean   Connor Don   Sabbagh Marwan   Seward Jim   Browne Patrick  

Publisher： Humana Press, Inc

ISSN： 0895-8696

Source： Journal of Molecular Neuroscience, Vol.20, Iss.3, 2003-08, pp. : 407-410

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Calpain inhibitors, a treatment for alzheimer’s disease: Position paper

By Battaglia Fortunato   Trinchese Fabrizio   Liu Shumin   Walter Sean   Nixon Ralph   Arancio Ottavio  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 357-362

Humana Press, Inc

Access to resources Recommend Favorite

Cholesterol, Copper and A&bgr; in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)

By  

Current Alzheimer Research, Vol. 2, Iss. 5, 2005-12 ,pp. : 527-539

Bentham Science Publishers

Access to resources Recommend Favorite

The BRAINz trial: a novel approach to acetylcholinesterase-inhibitor treatment for Alzheimer’s disease

By Wilkinson David   Roughan Laura  

Future Neurology, Vol. 2, Iss. 4, 2007-07 ,pp. : 379-382

Future Medicine

Access to resources Recommend Favorite

Alzheimer’s Disease and Cholesterol: The Fat Connection

By Canevari Laura   Clark John  

Neurochemical Research, Vol. 32, Iss. 4-5, 2007-04 ,pp. : 739-750

Springer Publishing Company

Access to resources Recommend Favorite

Alzheimer’s Disease—A Dysfunction in Cholesterol and Lipid Metabolism

By Lukiw Walter   Pappolla Miguel   Pelaez Ricardo   Bazan Nicolas  

Cellular and Molecular Neurobiology, Vol. 25, Iss. 3-4, 2005-06 ,pp. : 475-483

Springer Publishing Company

Access to resources Recommend Favorite